Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-17T00:16:08.523Z Has data issue: false hasContentIssue false
  • English
  • Français

Can carnitine treat fatigue?

Published online by Cambridge University Press:  11 September 2013

Get access

In a nutshell

Carnitine has been trialled as treatment for fatigue in a number of conditions, including renal dialysis, CFS and cancer.

The trend of results from these trials has been positive. But limitations in sample size, duration and design means the data collectively does not yet add up to a convincing case either way. Safety has so far not been a problem.

Type
Brief Report
Information
Arbor Clinical Nutrition Updates , Volume 287 , December 2007 , pp. 1 - 3
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Zwarts, MJ. et al. Clinical neurophysiology of fatigue. Clin Neurophysiol. 2008 Jan;119(1):2–10.Google Scholar
2. Helman, A. Carnitine for infertility and in diabetes. Arb Clin Nutr Upd. 2005;212:1–3.Google Scholar
3. Helman, A. Carnitine for Alzheimer's disease. Arb Clin Nutr Upd. 2005;230:1–2.Google Scholar
4. Anon Monograph. L-carnitine. Altern Med Rev. 2005 Mar;10(1):42–50.Google Scholar
5. Ames, BN. et al. Delaying the Mitochondrial Decay of Aging with Acetylcarnitine Ann. N.Y. Acad. Sci. 2004;1033:108–116.Google Scholar
6. Laviano, A. et al. Antimyopathic effects of carnitine and nicotine. Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):442–8.Google Scholar
7. Jones, MG. et al. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin Chim Acta. 2005 Oct;360(1-2):173–7.Google Scholar
8. Soetekouw, PM. et al. Normal carnitine levels in patients with chronic fatigue syndrome. Neth J Med. 2000 Jul;57(1):20–4.Google Scholar
9. Fukazawa, T. et al. Serum carnitine and disabling fatigue in multiple sclerosis. Psychiatry Clin Neurosci. 1996 Dec;50(6):323–5.CrossRefGoogle ScholarPubMed
10. Byrne, E. et al. Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle. J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):743–6.Google Scholar
11. Kuratsune, H. et al. Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage. 2002 Nov;17(3):1256–65.Google Scholar
12. Kuratsune, H. et al. Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int J Mol Med. 1998 Jul;2(1):51–6.Google Scholar
13. Plioplys, AV. et al. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology. 1995;32(3):132–8.Google Scholar
14. Ciacci, C. et al. L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study. Dig Liver Dis. 2007 Oct;39(10):922–8.Google Scholar
15. Rossini, M. et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol. 2007 Mar-Apr;25(2):182–8.Google Scholar
16. Lebrun, C. et al. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler. 2006 Jun;12(3):321–4.Google Scholar
17. Tomassini, V. et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004 Mar 15;218(1–2):103–8.Google Scholar
18. Vermeulen, RC. et al. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004 Mar-Apr;66(2):276–82.Google Scholar
19. Neri, S. et al. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology. 2003;47(2):94–7.Google Scholar
20. Graziano, F. et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer. 2002 Jun 17;86(12):1854–7.Google Scholar
21. Brass, EP. et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis. 2001 May;37(5):1018–28.Google Scholar
22. De Grandis, D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs. 2007;21 Suppl 1:39–43.Google Scholar
23. Youle, M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs. 2007;21 Suppl 1:25–30.CrossRefGoogle ScholarPubMed
24. Sima, AA. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs. 2007;21 Suppl 1:13–23.Google Scholar
25. Winter, SC. Treatment of carnitine deficiency. J Inherit Metab Dis. 2003;26(2–3):171–80.Google Scholar
26. Eknoyan, G. et al. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis. 2003 Apr;41(4):868–76.Google Scholar